Sales grew 6.4% year-over-year, with strong performance in pharmaceuticals, medical, and insurance segments, but net profit declined 15.1% due to financial and subsidiary impacts. Dividend of PLN 16 per share is recommended for 2025.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.